Back to Agenda
Ethics in the Era of Precision Medicine and Advancing Technologies
Session Chair(s)
James Wabby, MHS
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States
Precision medicine integrates advanced technology and healthcare to tailor treatments to individuals, aiming to enhance outcomes. However, the rise of artificial intelligence (AI) and advanced technologies in this field introduces new ethical complexities. Privacy, informed consent, and social justice remain central concerns, but evolving technologies brings additional challenges, such as biases in algorithmic predictions and the transparency of decision-making processes. AI-driven models used to predict treatment outcomes or develop personalized care plans can reflect societal biases if trained on unrepresentative or flawed data. This raises concerns about fairness, as patients could be unjustly stratified based on genetic, racial, or socioeconomic factors. Precision medicine, which stratifies patients by genetic profiles, risks perpetuating discrimination or exacerbating health disparities.
Learning Objective : Discuss the bioethical impact within the next generation of medicine; Recognize the importance of the inclusion of diverse, representative populations and handling of incidental findings.; Discuss how pharmaceutical company possesses its own data that can be explored, which is specific to their organization and reflective of their trial designs; Describe methods that have potential to enhance patient safety in RCTs by leveraging these unique datasets.
Speaker(s)
Panelist
Robert Danny Huntington, JD
ROTHWELL, FIGG, ERNST & MANBECK, P.C. , United States
Lawyer
Panelist
Scott Schell, MD, PHD, MBA, MPH
Cognizant, United States
Chief Medical Officer
Panelist
Ann Marie Hake, MD
Eli Lilly and Company, United States
Executive Director, Medical – Digital Health
Panelist
Chris Schneiderman, MPH
Abbvie, United States
Director, Data & Digital Convergence Catalyst
Have an account?